Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Popescu B, Jones MF, Piao M, Tran E, et al. Blood 2026;147:276-289.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Popescu B, Jones MF, Piao M, Tran E, et al. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood 2026;147:276-289.
PMID: 41144772